Closed-Loop Therapeutic Refinement Using Local Field Potentials in Parkinson's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-01

Study Completion Date

2027-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This multi-center pilot study compares conventional DBS (cDBS) and adaptive DBS (aDBS) in Parkinson's disease patients using the Medtronic Percept™ system.

The aim of the study is to identify which patients benefit most from aDBS, and to explore patient and LFP signal characteristics as well as stimulation parameters as potential predictors of treatment preference and efficacy. The study utilizes a blinded, randomized N-of-1 trial design, where each patient tests the following:

* Original cDBS settings (cDBS);
* Optimized cDBS settings (O-cDBS);
* Optimized aDBS settings (O-aDBS) Each setting is evaluated for a minimum of 2 and maximum of 7 days at home in a randomized order (patient blinded).

The main study outcome consists of the patient's final preference among the three DBS programs: original cDBS, O-cDBS, or O-aDBS. Secondary outcomes focus on differences between cDBS, O-cDBS and O-aDBS regarding the following parameters (among others):

* Quality of life (PDQ-39);
* Patient satisfaction (5-point Likert Scale);
* (Non)-motor fluctuations (MDS-UPDRS-III + MDS-NMS-Q);
* Time spent in "ON"/"OFF" motor phases (symptom diary + MDS-UPDRS IV);
* Time spent experiencing dyskinesia (symptom diary + MDS-UPDRS IV);
* Time spent with the most bothersome symptom (symptom diary + MDSUPDRS IV);
* Stimulation parameters;
* Local field potentials.

The study also incorporates real-world home-based assessments using the Experience Sampling Method (ESM) to capture motor and non-motor symptom fluctuations in daily life and identify differences among the three settings.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

LFP Correlates of Movement Disorders

NCT02115802

Parkinson's Disease

UNKNOWN NA

Adaptive Closed Loop Neuromodulation and Neural Signatures of Parkinson's Disease

NCT02384421

Parkinson's Disease

COMPLETED NA

Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease

NCT06909045

Deep Brain Stimulation Parkinson Disease

RECRUITING NA

Udall Project 2 Aim 2A&C

NCT05656586

Parkinson Disease

RECRUITING

Cortical Electrophysiology of Response Inhibition in Parkinson's Disease

NCT06234995

Parkinson Disease

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established treatment for patients with Parkinson's disease (PD), particularly for those experiencing motor fluctuations that do not respond adequately to medication. Optimal clinical outcomes depend on precise programming of stimulation parameters to effectively reduce motor symptoms, while avoiding side effects by minimizing stimulation of adjacent brain structures. During surgery, an electrode with eight contact points (1-3-3-1 design) is permanently implanted.

At the Haga Teaching Hospital, Maastricht UMC+, and Amsterdam UMC, the Medtronic Percept™ PC/RC system is commonly used for PD patients. This system provides not only stimulation but also the ability to record brain signals in the form of local field potentials (LFPs). This recording functionality can offer valuable insights for clinicians to fine-tune DBS parameters. For instance, elevated beta activity (13-35 Hz) in LFPs has been shown to correlate with the severity of symptoms such as rigidity and bradykinesia in PD patients.

In January 2025, a software update was introduced for the Percept™ system, enabling more advanced LFP measurements. This update allows the system to deliver adaptive DBS (aDBS), in which brain signals are used in real-time to continuously and automatically adjust stimulation amplitude. Although aDBS is a promising advancement, comprehensive research comparing its benefits and drawbacks to conventional DBS (cDBS) is still lacking. The only major study, ADAPT-PD, found that aDBS and cDBS result in similar durations of time spent in the "ON" phase, but it did not clarify which subgroup of patients benefits most from aDBS. Interestingly, many participants in the ADAPT-PD study expressed a desire to switch from cDBS to aDBS after the trial, though the factors influencing these preferences remain unclear. This highlights the need for detailed investigation into the relative advantages of aDBS and for whom the current form of aDBS provides the greatest benefit.

This study targets PD patients who have undergone cDBS for at least six months but are not experiencing optimal results due to persistent motor symptoms or stimulation-induced side effects that are insufficiently addressed by standard cDBS. Within this pilot study, using a combined N-of-1 trial design, outcomes of the patient's current cDBS settings and optimized conventional DBS (O-cDBS) will be objectively compared with those of optimized adaptive DBS (O-aDBS).

In an N-of-1 trial, an individual patient undergoes different test and placebo treatments in a randomized order. By conducting multiple N-of-1 trials across several patients, reliable and objective outcomes can be gathered both at the individual and population levels. In this study, each patient will test all three stimulation programs (current cDBS, O-cDBS, and O-aDBS) in a blinded and randomized sequence, each for seven days. The final outcome will be the patient's preferred program, with the patient's personal choice taking priority. To better understand the impact of switching from cDBS to aDBS-and to include effects on patient quality of life-this study will analyze not only motor symptoms but also cognitive and behavioral effects in daily life. This will be assessed through structured questionnaires, including a symptom diary and questions via the Experience Sampling Method (ESM). ESM is a validated, CE-certified digital diary method where patients provide feedback on the patient's symptoms at semi-random times, helping to reduce recall bias. By objectively analyzing the pros and cons of switching from cDBS to aDBS in these specific patient groups, this study aims to support neurologists in the clinical use of this new technology. Furthermore, the findings may contribute to more effective use of the system and ultimately to improved DBS treatment and quality of life for patients with Parkinson's disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease (PD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

An N-of-1 trial design in which each patient tests conventional DBS, optimized conventional DBS, and optimized adaptive DBS for seven days each, in a blinded and randomized sequence.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Patients are not masked for the group they are in, but they are blinded for the order in which they receive treatment with three different deep brain stimulation settings.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

N-of-1 study arm

Main study arm where each participant tests conventional DBS, optimized conventional DBS, and optimized adaptive DBS for seven days each, in a blinded and randomized sequence

Group Type EXPERIMENTAL

Conventional DBS

Intervention Type DEVICE

Treatment for a minimum of 2 to a maximum of 7 days with the patient's original conventional DBS (cDBS) settings.

Optimized conventional DBS

Intervention Type DEVICE

Treatment for a minimum of 2 to a maximum of 7 days with a previously optimized version of the patient's original conventional DBS (O-cDBS) settings.

Optimized adaptive DBS

Intervention Type DEVICE

Treatment for a minimum of 2 to a maximum of 7 days with previously optimized adaptive DBS (O-aDBS) settings.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Conventional DBS

Treatment for a minimum of 2 to a maximum of 7 days with the patient's original conventional DBS (cDBS) settings.

Intervention Type DEVICE

Optimized conventional DBS

Treatment for a minimum of 2 to a maximum of 7 days with a previously optimized version of the patient's original conventional DBS (O-cDBS) settings.

Intervention Type DEVICE

Optimized adaptive DBS

Treatment for a minimum of 2 to a maximum of 7 days with previously optimized adaptive DBS (O-aDBS) settings.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with Parkinson's disease with bilateral DBS in the STN
* DBS surgery with implantation of the Percept™ PC/RC system performed at least 6 months ago
* Symptoms such as dysarthria, freezing, or ON-OFF fluctuations that are insufficiently controlled
* A usable LFP signal is present on at least one side

Exclusion Criteria

* Patients for whom switching to aDBS, operating the remote control independently, or making regular visits to the DBS center is deemed clinically unsafe or unreliable by the treating physician - for example, due to active or unstable cognitive or psychiatric conditions.
* High impedance, defective DBS electrodes, or insufficient LFP signal quality, or bilateral stimulation primarily on the most ventral or dorsal contact points, preventing proper functioning of aDBS.
* Patients who have objected to the use of their electronic health record data for medical scientific research.

Eligible Sex

ALL

Accepts Healthy Volunteers

No